Approval · Notice of Compliance 17030 · 2015
OFEV: Notice of Compliance 17030
Issued June 25, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17030
- Date
- June 25, 2015
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Therapeutic class
- Protein kinase inhibitor
Products in this notice
Medicinal ingredients
- NINTEDANIB 100 MG per CAP
- NINTEDANIB 150 MG per CAP